PDCD1 and glioblastoma: It is worth mentioning here that the expression of such markers can rapidly change in association with treatment, as indicated by the results of studies in which GBM patients received co-treatment with rapamycin and hydroxychloroquine or concurrent stereotactic radiotherapy with immune checkpoint blockade via programmed cell death protein 1 (PD-1) signal disruption (40, 41).